Incyte's Opzelura received approval in the United States on June 23, 2025, and the FDA extended the review for the company's sNDA.
2 reports, 0 independent
Updated Jun 23
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Incyte's Opzelura received approval in the United States on June 23, 2025, and the FDA extended the review for the company's sNDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Incyte
American pharmaceutical company
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet